2022
Treatment patterns and medical costs of metastatic breast cancer care in the United States.
Chehayeb R, Hood A, Mougalian S, Lustberg M, Wang S, Greenup R, Pusztai L, Kunst N. Treatment patterns and medical costs of metastatic breast cancer care in the United States. Journal Of Clinical Oncology 2022, 40: e18834-e18834. DOI: 10.1200/jco.2022.40.16_suppl.e18834.Peer-Reviewed Original ResearchMetastatic breast cancerTreatment patternsTreatment costsDiagnosis of MBCSocietal perspectiveHormone receptor statusBreast cancer careDays of diagnosisDe-identified databaseAverage wholesale priceElectronic health recordsMBC patientsMBC diagnosisReceptor statusCancer careInvasive cancerTriple NegativeClinical trialsReceptor subtypesPatient levelBreast cancerHuman epidermal growth factorPayer perspectiveDrug costsEpidermal growth factor
2017
The epidemiology of metaplastic breast cancer: A review of 2,500 cases from the national cancer database.
Campbell B, Thomas S, Ong C, Greenup R, Plichta J, Rosenberger L, Force J, Hyslop T, Hwang E, Fayanju O. The epidemiology of metaplastic breast cancer: A review of 2,500 cases from the national cancer database. Journal Of Clinical Oncology 2017, 35: 1570-1570. DOI: 10.1200/jco.2017.35.15_suppl.1570.Peer-Reviewed Original ResearchMetaplastic breast cancerNational Cancer DatabaseTriple-negative breast cancerMBC patientsBreast cancerMBC diagnosisReceptor statusCancer DatabaseAcademic centersSociodemographic factorsHigher clinical T stageFemale breast cancer patientsAdult female breast cancer patientsClinical T stageClinical N stageBreast cancer patientsMultivariate logistic regressionPopulation-based analysisCox proportional hazardsGovernment-sponsored insuranceNon-Hispanic blacksLow socioeconomic statusPaucity of dataOverall survivalWorse survival
2014
Use and duration of chemotherapy in patients with metastatic breast cancer according to tumor subtype and line of therapy.
Seah DS, Luis IV, Macrae E, Sohl J, Litsas G, Winer EP, Lin NU, Burstein HJ. Use and duration of chemotherapy in patients with metastatic breast cancer according to tumor subtype and line of therapy. Journal Of The National Comprehensive Cancer Network 2014, 12: 71-80. PMID: 24453294, DOI: 10.6004/jnccn.2014.0008.Peer-Reviewed Original ResearchMeSH KeywordsAdultAgedAged, 80 and overAntibodies, Monoclonal, HumanizedAntineoplastic Combined Chemotherapy ProtocolsChemotherapy, AdjuvantDisease-Free SurvivalFemaleHumansMiddle AgedNeoplasm MetastasisNeoplasm StagingReceptor, ErbB-2Receptors, EstrogenReceptors, ProgesteroneTriple Negative Breast NeoplasmsConceptsMetastatic breast cancerDuration of chemotherapyLines of therapyBreast cancerTumor subtypesDana-Farber Cancer InstituteSixth-line therapyMedian overall survivalBenefit of chemotherapyResult of progressionWarrants further studyChemotherapy linesChemotherapy regimenProlonged therapyMBC diagnosisMedian durationOverall survivalClinicopathologic characteristicsConsecutive patientsMedian ageClinical benefitMedical recordsChemotherapyCancer InstitutePatients
This site is protected by hCaptcha and its Privacy Policy and Terms of Service apply